Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The Lancet Oncology

These externally validated nomograms that are predictive of outcomes after 177Lu-PSMA in patients with mCRPC might help in clinical trial design and individual clinical decision making, particularly at institutions where 177Lu-PSMA is introduced as a novel therapeutic option.

  • There’s a lot of excitement about PSMA based therapies and everyone is coming in asking about it. Helpful to see this article to include in the discussion with patients about what factors are associated with the best outcomes from this therapy so far.